Modality
Multispecific
MOA
ALKi
Target
CD20
Pathway
Complement
ThymomaEoE
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jun 2028
Phase 1Current
NCT04299439
2,736 pts·EoE
2021-10→2028-06·Not yet recruiting
NCT03811854
1,493 pts·Thymoma
2018-02→2025-06·Not yet recruiting
4,229 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-1210mo agoInterim· Thymoma
2028-06-242.2y awayInterim· EoE
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Not yet…
P1
Not yet…
Catalysts
Interim
2025-06-12 · 10mo ago
Thymoma
Interim
2028-06-24 · 2.2y away
EoE
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04299439 | Phase 1 | EoE | Not yet recr... | 2736 | NT-proBNP |
| NCT03811854 | Phase 1 | Thymoma | Not yet recr... | 1493 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |